Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma Complicated by Extramedullary Plasmacytoma
Latest Information Update: 08 May 2025
At a glance
- Drugs Velinotamig (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Therapeutic Use
- Sponsors Genrix (Shanghai) Biopharmaceuticals
Most Recent Events
- 08 May 2025 New trial record